ClinicalTrials.gg
Active, not recruitingNCT03937700Updated May 11, 2026

Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker

An interventional study of CPWalker Robotic Exoskeleton in Cerebral Palsy, sponsored by Shirley Ryan AbilityLab. Active, not recruiting at 1 site in United States. Open to participants aged 11 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
11 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 372 studies in Cerebral Palsy with a site in United States — 74 open to participants now, 102 under way, none of them phase 3. Cerebral Palsy · United States.

Planned enrollment
130th of 296
30 · median 25
Started
2019
with 19 others
No phase
218 of 372
49 open now
Primary completion
2026-12
later than 36 of 101 live
Registered
188th of 372
by date

Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 130th largest by planned enrollment of the 296 interventional ones that give a count, is one of 20 that started in 2019, is one of 218 with no phase, reaches primary completion later than 36 of the 101 other live ones, and was the 188th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

74 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 11 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 372 studies in Cerebral Palsy with a site in United States, or all of them as a file.
02

Study summary

This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy

Read the detailed description

Objectives:

  1. To determine the use of the CPWalker rehabilitation platform, a robotic device composed by an exoskeleton linked to a walker that provides support and balance, as a gait training intervention in the pediatric cerebral palsy population.
  2. To create and define detailed guidelines consisting of robotic based treatment methods for gait rehabilitation.

Hypothesis:

  1. CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy
  2. Performing lower limb training in conjunction with active head and trunk control therapies will improve functional gait levels
  3. Following 16-24 CPWalker training sessions, persons with cerebral palsy will show improvements in functional mobility when comparing pre-training measurements to post-training measurements

Procedures:

Participants will engage in an 8-week training program, consisting of 2-3 sessions per week based on the level of gait impairment. Percentage range of motion (ROM), partial body weight support (PWBS), and gait velocity are the principal parameters under variation during training.

Additionally, screening, baseline and post-training testing sessions will be conducted

03

Conditions studied

  • Cerebral Palsy

Browse trials for

04

Who can participate

Ages eligible
11 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Cerebral Palsy with spastic diplegia
  • Gross Motor Function Classification System score of 2-4
  • Age 11-21 at time of enrollment
  • Maximum weight of 75kg
  • Height range of approximately 110cm to 170cm
  • Ability to understand and follow verbal cues
  • Lower limb measurements meet specifications of CPWalker
  • Cognition sufficient to communicate pain or discomfort and follow one step direction from the investigator

Exclusion criteria

Exclusion Criteria:

  • Any orthopedic surgeries less than 3 months prior to study enrollment or ongoing botox injections
  • Severe musculoskeletal deformities affecting safe and comfortable fit into the exoskeleton as determined by the investigator. Patients may be able to wear their AFOs in the CPWalker if it allows for safe fit.
  • Unhealed wounds/lesions
  • Critical motor control alterations such as dystonia, choreoathetosis, or ataxia
  • Aggressive or self-harming behavior
  • Severe cognitive impairments that prevent a subject from being able to understand the exercises an/or interact with the study staff
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CPWalker Robotic-Assisted Gait Training

    Each subject will participate in 16-24 gait training sessions in the CPWalker over the course of 8 weeks with each session lasting up to 2 hours

    Device: CPWalker Robotic Exoskeleton

Interventions

  • DeviceCPWalker Robotic Exoskeleton

    The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance

06

What researchers measure

Primary outcomes

  1. 10-Meter Walk Test

    This test will examine the patient's gait speed. Patients will be directed to walk at their preferred and maximum but safe speed. Patients will be positioned 1 meter before the start line and instructed to walk the entire 10-meter distance and past the end line approximately 1 meter. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be recorded using a stopwatch and recorded to the one hundredth of a second.

    Time frame: Change from baseline gait speed at 8 weeks

Secondary outcomes

  1. 6-Minute Walk Test

    This test measures the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The test is patient self-paced and assesses the level of functional capacity. Patients are allowed to stop and rest during the test, however, the timer does not stop. If the patient is unable to complete the time, the time stopped is noted and reason for stopping prematurely is recorded. This test will be administered while wearing a mask to measure oxygen consumption.

    Time frame: Change from baseline distance ambulated at 8 weeks

  2. GAITRite Data Collection

    The GAITRite system automates measuring temporal and spatial gait parameters via an electronic walkway connected to a computer. The GAITRite electronic walkway contains sensor pads encapsulated in a carpet to collect gait information. The system can be laid over any flat surface. The GAITRite electronic walkway for the study shall be a minimum of 14 feet long. The GAITRite data capture was chosen as measurement of the patient's overall gait quality. Patients will be asked to walk at a self-selected speed across the GAITRite electronic walkway with at least a two meter "flying start" to compensate for initial acceleration.

    Time frame: Change from baseline gait quality at 8 weeks

  3. Pediatric Balance Scale

    This test is a 14-item objective measure designed to assess static balance in pediatric populations. The functional activities that are assessed include sitting and standing balance during transfers, altered base of support, reaching, turning, eyes open and closed. Each item is scored from 0 to 4 points. The maximum score is 56 points.

    Time frame: Change from baseline balance score at 8 weeks

  4. Selective Control Assessment of Lower Extremity (SCALE)

    This clinical tool quantifies selective voluntary motor control of the lower extremities in patients with cerebral palsy.

    Time frame: Change from baseline selective voluntary motor control at 8 weeks

  5. Gross Motor Function Measure (GMFM-88) dimensions D (standing) and E (walking)

    This test measures the change in gross motor function with intervention in children with cerebral palsy

    Time frame: Change from baseline gross motor function at 8 weeks

  6. Child and Adolescent Scale of Participation

    This questionnaire measures the extent to which children participate in home, school, and community activities as reported by family caregivers.

    Time frame: Change in children's baseline participation in activities at 8 weeks

  7. Gillette Functional Assessment Questionnaire (FAQ)

    This is a proxy-report measure that includes a ten-level classification of ambulatory function and 22 functional locomotor activities

    Time frame: Change in baseline report of ambulatory function at 8 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Dec 2026, 89 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 89 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2019
First posted
May 6, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03937700
Responsible party
Arun Jayaraman, PT, PhD (Research Scientist, Shirley Ryan AbilityLab) — Principal investigator
First posted
May 6, 2019
Start date
Jul 1, 2019
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 11, 2026

Study contacts

Arun Jayaraman, PT, PhD
principal investigator · Shirley Ryan AbilityLab

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion